Cerebral small vessel disease research and family advocacy
Developing Treatments for Genetic Cerebral Small Vessel Disease
CSVD Therapeutics is a patient-led research and education platform connecting families, clinicians and scientists to develop therapies for inherited cerebral small vessel disease (CSVD), including NOTCH3-related CADASIL and COL4A1/COL4A2-related disorders. These therapies are under development.
A platform for CSVD families, clinicians, and scientists working towards gene-targeted therapies.
Patient partnership keeps the lived experience of inherited CSVD close to research priorities. We combine disease biology with experimental gene and RNA therapies and drug repurposing, building evidence before candidate treatments can move towards clinical studies.
Start with the leadership team, the collagen-related disorders and CADASIL projects, or the therapeutic development pathway for research readiness.
Understand cerebral small vessel disease: explore its causes, inheritance, current care and the difference between laboratory research and patient studies.
Who we are
A home for CSVD families and the researchers working beside them.
CSVD Therapeutics is a patient-led research and education platform focused on practical progress: better data, better models, better trial readiness, and a serious exploration of gene-targeted approaches for NOTCH3-related CADASIL and COL4A1/COL4A2-related disorders. These approaches remain under development.
The work is designed around collaboration: families who understand the lived reality of CSVD, clinicians who see the disease course, and scientists developing the tools that could change it.
Our purpose
Turning urgency into organised scientific momentum.
CSVD Therapeutics brings together patient advocacy, translational neuroscience, and cerebrovascular research to help move CSVD towards credible therapeutic progress.
